Brenner Erin K. 4
4 · Pear Therapeutics, Inc. · Filed May 27, 2022
Insider Transaction Report
Form 4
Brenner Erin K.
Chief Product Dev. Officer
Transactions
- Exercise/Conversion
Common Stock
2022-05-25$1.00/sh+15,000$15,000→ 15,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-05-25−15,000→ 105,234 totalExercise: $1.00Exp: 2028-09-20→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]25% of the shares underlying the option vested on July 16, 2019 and an additional 2.0833 and 1/3% of the shares vested or shall vest on the last day of each calendar month thereafter.
- [F2]Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 81,659 shares of common stock of Private Pear for $1.46 per share.